Healthcare Industry News’ Post

This is a great article from Pierre Arsène, he is on the money that the future of healthcare is even more orientated towards prevention over cure and that requires significant investment in diagnostics. Looking at Liver Disease alone is a signficant area of cost rivalling other areas considered way more critical. Cirrhosis costs the U.S. healthcare system as much as heart failure. Healthcare reimbursement is shifting from fee-for-service to fee-for-value and EVs should enable that EV's (#ExtracellularVesicles) offer this potential benefit at scale and with accessibility. and there are a lot of papers in the management of chronic diseases that discuss the need to do things better to avoid litigation and other costs associated with poor care which derives from poor diagnostic management. Liability is one such area of cost:- EV's should be that game changing model and Mursla Bio are best positioned to exploit that.

Engineering lipid nanoparticles for #lungcancerimaging Early detection of lung cancer significantly improves survival rates, yet only 27% of all lung cancers are diagnosed at Stages 1-2. This is partly due to the lack of highly accurate, non-invasive diagnostic imaging methods that can differentiate malignant cancers from benign lesions. Join Blaine McCarthy (Team Lead, Delivery, Earli Inc.), Sushil Lathwal (Senior Scientist, Earli Inc.), and Ben Knappett (Market Manager of LNPs, Unchained Labs) as they introduce the workflow used to engineer #lipidnanoparticles (#LNPs) to deliver cancer-activated #DNAvectors that produce synthetic biomarkers for #cancerimaging. Register for this #webinar below:

Engineering lipid nanoparticles for #lungcancerimaging Early detection of lung cancer significantly improves survival rates, yet only 27% of all lung cancers are diagnosed at Stages 1-2. This is partly due to the lack of highly accurate, non-invasive diagnostic imaging methods that can differentiate malignant cancers from benign lesions. Next month, join Blaine McCarthy (Team Lead, Delivery, Earli Inc.), Sushil Lathwal (Senior Scientist, Earli Inc.), and Ben Knappett (Market Manager of LNPs, Unchained Labs) as they introduce the workflow used to engineer #lipidnanoparticles (#LNPs) to deliver cancer-activated #DNAvectors that produce synthetic biomarkers for #cancerimaging. Register for this #webinar below:

CTC diagnostics involves the detection and analysis of cancer cells that have broken away from the primary tumor and are circulating in the bloodstream. These cells provide invaluable insights into the progression of cancer, enabling oncologists to monitor the disease in real-time, tailor treatments to individual patients, and potentially improve outcomes.   Top Global Circulating Tumor Cell Diagnostics Industry Players: QIAGEN Bio-Techne Precision For Medicine BioCep Greiner Bio-One International Ikonisys Miltenyi Biotec BioFluidica, Inc. Biolidics Limited (Formerly known as Clearbridge BioMedics) Epic Sciences Rarecells ScreenCell Menarini Silicon Biosystems Vitatex Inc   Read More @ https://lnkd.in/dz9zMhuj   #ctcdiagnostics #liquidbiopsy #precisionmedicine #cancerdiagnostics #oncology #biotechnology #medtech #ctc #marketgrowth#liquidbiopsy #personalizedmedicinerevolution #healthcare #investinginhealthcare #ctcdrugdevelopment #earlycancerdetection #residualdisease #cancertreatment #startup #metastatinsight

One of the key topic areas at #WORLDCDX includes CDx in ADCs. #Geneexpression will play a critical role in the development of ADC therapies, the next generation of immunotherapies that hold huge potential for cancer patients. Understanding #transcriptomics data to reveal tumor heterogeneity, immune responses and biomarkers discovery are diverse areas where latest #cfRNA NGS technologies can be utilized to accelerate ADC drug development. Sysmex Inostics’ broad portfolio of comprehensive cfRNA plus cfDNA panels can provide unique solutions to your liquid biopsy needs for ADCs. Come speak with our experts to learn how we can expedite your ADC clinical trials! https://hubs.la/Q02L8G6-0 #cellfreeDNA #ADCs #ADCclinicaltrial

📰 🎙️ In an exclusive Q&A with Drug Target Review, our CEO Dr. Alan D. Roth discusses how Oxford Drug Design achieved the first in vivo validation for a potential first-in-class cancer treatment. Our 28-day mouse trial demonstrated clear efficacy and dose response, made possible by our dual-competency discovery platform, which combines generative AI with deep expertise in tRNA synthetases. Alan delves into the trial results, how this breakthrough could transform therapeutic options for multiple tumours, and the role of our cutting-edge AI platform, SynthAI, in revolutionising drug discovery. Read the full interview here 👉 https://lnkd.in/eGsBDNZA #AI #drugdiscovery #cancerresearch #biotech #pharmaceuticalindustry

New Research Alert: At insitro, we are deploying novel machine learning methods to better understand the complexities of cancer, a key step towards developing new and effective treatments. Our recently published paper, "Machine Learning-Enabled Prediction of Digital Biomarkers from Whole Slide Histopathology Images," details our approach to leveraging #ML and broad patient data to identify biomarkers that effectively stratify patients to enable the effective, targeted delivery of therapeutics and biomarker-informed design of new investigative medicines. https://lnkd.in/gNugZfKV

Tumor heterogeneity poses a formidable challenge in #cancer therapy and drives disease progression. The application of single-cell #omics is an indispensable tool for unraveling #tumor microenvironments, thus advancing disease insights and devising potential therapeutic strategies. #cancerresearch #singlecellanalysis #bioinformatics #medical #dataanalysis

Craving Data? Check out our webinar on methylation analysis of liquid biopsies using Droplet Digital™ PCR! 📅 Date: April 18, 2024 🕒Time: 15:00 CEST (06:00 PDT) 🌐Register: https://ow.ly/hHzT50R9Izm Talk Abstract: Highly sensitive methods with a short turn-around-time are needed to guide treatment of cancer patients. The talk will describe the options which can be used to perform methylation analyses using Droplet Digital PCR. The use of circulating cell-free DNA will be discussed to monitor cancer patients in the metastatic setting. Measurements of circulating tumor DNA may supplement imaging for response evaluation and assist clinicians in tailoring treatment to individual patients. Don't miss out on this opportunity to gain valuable insights and engage with experts in the field! #EACR #CancerResearch #ddPCR

"But it worked" Dr. Carl June, the "father of CAR-T cell therapy", in his own words to The Medicine Maker upon receiving the Advanced Therapies Lifetime Achievement Award 🏆 "No one could have predicted what has happened in CAR T – for many reasons. For one thing, it actually worked a lot better in our initial trials in humans than it had worked in mice. [] Also, back in the 1990s, there were only about five labs working on CAR T cells. There was no pharmaceutical industry involvement back then, and for the academics (including my own lab) that were working on the topic, it was more of an academic thought experiment: Could you redirect a T cell and use it to treat cancer? We weren’t necessarily thinking it would or could ever be commercialized, but it worked. Back then, there was no cell therapy industry – but now there is. And the statistics are amazing." University of Pennsylvania School of Medicine #celltherapy #curecancer #legend 👇 Link ▶ https://lnkd.in/ejxvyeBX